menu
    • menu

    Company profile for SIGA Technologies

    NEW Drugs in Dev: 1
    ChemWerth works in generic API development & supply, non-infringement patent strategy development and regulatory support.

    Virtual Booth

    Contact Supplier

    AbbVie CDMO has been working with global companies to develop, manufacture & scale biopharmaceutical products.

    Virtual Booth

    Contact Supplier

    Lupin Manufacturing Solutions – delivering high-quality APIs & end-to-end CDMO services for faster, cost-effective drug development.

    Virtual Booth

    Contact Supplier

    Minakem delivers API, HPAPI, steroids & CDMO services for generics with FDA/GMP certification, regulatory know-how & proven success.

    Virtual Booth

    Contact Supplier

    LGM Pharma accelerates & optimizes the new product pathway from early development through commercialization.

    Virtual Booth

    Contact Supplier

    pharmacompass-2-m-2026-03-23

    Virtual Booth

    Contact Supplier

    EVENTS

    DIGITAL CONTENT

    DEVELOPMENTS

    FINISHED DOSAGE FORMULATIONS

    INSPECTIONS & REGISTRATIONS

    PharmaCompass

    Only Regulatory Products (API/FDF), Drugs in Developments and News are Updated on this Virtual Booth

    Update your Virtual Booth on PharmaCompass, ask us

    About

    SIGA Technologies is a company specializing in the development and commercialization of solutions for serious unmet medical needs and biothreats. Our lead product is TPOXX® (USAN tecovirimat, ST-246®), an orally administered antiviral drug that targets orthopoxvirus infections. TPOXX has been approved by the FDA for the treatment of human smallpox disease. It is a novel small-molecule drug that is being delivered to the St...
    SIGA Technologies is a company specializing in the development and commercialization of solutions for serious unmet medical needs and biothreats. Our lead product is TPOXX® (USAN tecovirimat, ST-246®), an orally administered antiviral drug that targets orthopoxvirus infections. TPOXX has been approved by the FDA for the treatment of human smallpox disease. It is a novel small-molecule drug that is being delivered to the Strategic National Stockpile under Project BioShield.

    List your booth number for exhibitions, ask us

    CONTACT DETAILS

    Click the arrow to open the dropdown
    Contact SupplierContact
    Google MapGoogle Map
    Full View ScreenFull View Screen
    SIGA TechnologiesUnited_States_of_America Flag
    Country
    Country
    U.S.A
    Address
    Address
    27 East 62nd Street New York, NY 10065
    Telephone
    Telephone
    Client Email
    Email
    enquiries@pharmacompass.com
    Client Website
    Website
    https://www.siga.com/
    Linkedin
    Linkedin
    youtube
    YouTube
    Twitter
    Twitter

    Upload your Marketing & Sales content on your company Virtual Booth, click HERE.

    Events

    Webinars & Exhibitions

    Request a meetingRequest a meeting
    Full Screen ViewFull Screen View
    Default Event

    IPhEB Russia

    Not Confirmed

    envelop Contact Supplier

    IPhEB Russia

    Post an Enquiry

    Meeting

    Digital content

    Create Content with PharmaCompass, ask us

    NEWS #PharmaBuzz

    read-more
    read-more
    SIGA Declares Special Cash Dividend Of $0.60 Per Share
    SIGA Declares Special Cash Dividend Of $0.60 Per Share

    26 Mar 2026

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2026/03/26/3263383/9738/en/SIGA-Declares-Special-Cash-Dividend-of-0-60-Per-Share.html

    GLOBENEWSWIRE
    26 Mar 2026
    Share Share
    SIGA Reports Financial Results For Q4 2025 And Business Update
    SIGA Reports Financial Results For Q4 2025 And Business Update

    10 Mar 2026

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2026/03/10/3253295/9738/en/SIGA-Reports-Financial-Results-for-Three-and-Twelve-Months-Ended-December-31-2025-and-Provides-Business-Update.html

    GLOBENEWSWIRE
    10 Mar 2026
    Share Share
    SIGA To Host Business Update Call Post 2025 Financial Results
    SIGA To Host Business Update Call Post 2025 Financial Results

    03 Mar 2026

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2026/03/03/3248215/9738/en/SIGA-to-Host-Business-Update-Call-on-March-10-2026-Following-Release-of-2025-Financial-Results.html

    GLOBENEWSWIRE
    03 Mar 2026
    Share Share
    SIGA Releases Financial Results For Q3 & 9M 2025
    SIGA Releases Financial Results For Q3 & 9M 2025

    06 Nov 2025

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2025/11/06/3183044/9738/en/SIGA-Reports-Financial-Results-for-Three-and-Nine-Months-Ended-September-30-2025.html

    GLOBENEWSWIRE
    06 Nov 2025
    Share Share
    SIGA To Host Business Update Call Post Third-Quarter 2025 Results
    SIGA To Host Business Update Call Post Third-Quarter 2025 Results

    30 Oct 2025

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2025/10/30/3177277/9738/en/SIGA-to-Host-Business-Update-Call-on-November-6-2025-Following-Release-of-Third-Quarter-2025-Results.html

    GLOBENEWSWIRE
    30 Oct 2025
    Share Share
    Siga Reports Financial Results for June 30, 2025 Period
    Siga Reports Financial Results for June 30, 2025 Period

    05 Aug 2025

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2025/08/05/3127799/9738/en/SIGA-Reports-Financial-Results-for-Three-and-Six-Months-Ended-June-30-2025.html

    GLOBENEWSWIRE
    05 Aug 2025
    Share Share

    Inspections and registrations

    Upload your audits for free, ask us

    ABOUT THIS PAGE

    Ask Us for Pharmaceutical Supplier and Partner
    Ask Us, Find A Supplier / Partner
    No Commissions, No Strings Attached, Get Connected for FREE

    What are you looking for?

    How can we help you?

    The request can't be empty

    Please read our Privacy Policy carefully

    You must agree to the privacy policy

    The name can't be empty
    The company can't be empty.
    The email can't be empty Please enter a valid email.
    The mobile can't be empty
    • Privacy policy
    • Terms and conditions
    • Disclaimers
    • LinkedIn
    • Product listings are provided for informational purposes only. We do not supply or sell any products. Any products that may be covered by patent(s) are supplied solely for uses permitted under Section 107A of the Indian Patents Act and not for commercial sale.

    Market Place

    Market Place

    PharmaCompass

    Home

    Market Place

    Menu

    Post Enquiry

    Post Enquiry

    Market Place

    Market Place

    Search